Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising ...

Moderna Inc MRNA shares are trading higher during Monday’s pre-market session as investors focus shifts to an emerging global ...

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports ...

Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), making it the ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near ...